Company
Boston Scientific Corp
NYSE:BSX
Boston Scientific Corp is a developer, manufacturer and marketer of medical devices. The company’s segments include MedSurg and Cardiovascular.
21 stories
Dow plunges over 1,100 points as Fed’s hawkish hold sends yields higher
A busy afternoon of earnings from Meta and Microsoft comes as the Fed holds rates
Boston Scientific rises as preliminary 4Q sales figures match consensus estimate
For all of 2018, the company reported an 8.6% gain in preliminary sales to $9.82 billion
Jefferies downgrades BTG as it rules out bidding war for the UK pharma group
Analysts at the US investment bank said in a note that they don’t expect any other bidders to come forward, so have cut their rating and target to reflect that
Webis weak on limited California license renewal; Kier Group drops on cash call
A look at some winners and losers in the UK equity market on Friday
FTSE 100 closes lower as G20 summit begins and trade worries continue; housebuilders fall
The premier index of UK shares finished down nearly 59 points at 6,980. Mid-cap cousin FTSE 250 shed over 128 points at 18,480.
Boston Scientific eyes medical devices growth with £3.3bn BTG acquisition
BTG said it plans to recommend the 840p per share deal to its shareholders as it considers the terms to be fair and reasonable
Hardware & electrical equipment
Tekcapital's blue-chip hires
The top teams at Tekcapital's investee companies exude quality
Investments and investor services
Small-Cap Snapshot: Medical device company Nevro is on the rise after a court rules in its favor
The company has been involved in a patent infringement litigation suit with Boston Scientific
PRE-MARKET MOVERS: General Motors shares take foot off the gas after guidance, while Usana Health Sciences stock perks up
Also in play in pre-market trade is fizzy drinks giant The Coca-Cola Co and Boston Scientific Corp
Stryker makes a takeover offer for Boston Scientific, says a WSJ report
If the companies merge, the new group's yearly sales would amount to over US$20bn based on 2017 results
Boston Scientific shares halted on takeover talk
A Wall Street Journal report says it’s unclear whether the device maker was receptive to an overture by rival Stryker
Boston Scientific beefs up urology portfolio with acquisition of NxThera for up to US$406mln
Privately-held NxThera has developed the Rezūm system, which uses water vapor to remove excess prostate tissue and reduce symptoms related to benign prostatic hyperplasia
Boston Scientific makes loss after taking charge for tax changes
Adjusted fourth quarter earnings per share rose to US$0.34 from US$0.30 a year ago
Boston Scientific tops forecasts with third quarter sales
“Our global team is delivering strong performance as we continue to invest in a deep and innovative portfolio and expand into faster-growing markets”
Bed Bath & Beyond, FedEx, Adobe Systems and more - AFTER HOURS
Proactive takes a look at what was moving the market after hours in New York